Europe Companion Diagnostics Market Industry Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Companion diagnostics are in vitro diagnostic devices or tools that provide information essential for the safe and effective use of corresponding targeted therapies. These tests help determine which patients will respond to a particular drug based on their genetic or molecular profile, most commonly in oncology but also in neurology and other therapeutic areas. Europe represents the second-largest regional market globally, benefiting from a well-established pharmaceutical industry, universal healthcare coverage, and strong regulatory frameworks that support innovative diagnostics.

• •The market is projected to reach between $2.2 billion and $3.6 billion by 2030-2033 depending on scope and methodology
• •Oncology applications dominate the market, driven by the proliferation of targeted cancer therapies and immunotherapies
• •National precision medicine initiatives across the EU are accelerating adoption of companion diagnostic testing

The rising global prevalence of cancer and other chronic diseases is increasing demand for personalized treatment approaches that minimize adverse effects and improve patient outcomes. Advances in next-generation sequencing and polymerase chain reaction technologies have made genetic testing faster, cheaper, and more accurate, enabling wider clinical adoption. Regulatory developments including the EU In Vitro Diagnostic Regulation have established clearer pathways for companion diagnostic approval while maintaining rigorous safety standards.

• •Pharmaceutical companies are increasingly required to develop companion diagnostics alongside their targeted therapies to gain market authorization
• •Growing collaborations between biopharmaceutical firms and diagnostic companies are creating integrated treatment-diagnosis solutions
• •Reimbursement policies in major European markets are gradually adapting to cover companion diagnostic testing for approved therapies

The market is segmented by technology including polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), and in situ hybridization methods, each serving different clinical and research applications. By product type, the market includes assay kits, reagents, instruments, and software platforms that support diagnostic laboratories. Western Europe, particularly Germany, France, and the United Kingdom, commands the largest regional share, though Eastern European markets are growing as healthcare infrastructure and precision medicine programs expand.

• •PCR and NGS technologies together account for the majority of market revenue due to their accuracy and throughput capabilities
• •The UK, Germany, and France represent the three largest national markets in Europe
• •Immunohistochemistry remains important for protein-based companion diagnostics, especially in solid tumor profiling

What are the recent trends and outlook?

The market is moving toward comprehensive genomic profiling and liquid biopsy technologies that enable non-invasive, real-time monitoring of patient responses to therapy. Multiplex tests that assess multiple biomarkers simultaneously are gaining favor as clinicians seek broader molecular profiling from single samples. Over the coming decade, the expansion of biobanking infrastructure, artificial intelligence integration in test interpretation, and broader reimbursement coverage are expected to further accelerate market growth across European healthcare systems.

• •Liquid biopsy companion diagnostics using circulating tumor DNA are emerging as a significant growth segment
• •AI and machine learning tools are being applied to improve biomarker identification and test result interpretation
• •The pipeline of targeted therapies requiring companion diagnostics continues to expand, ensuring sustained long-term demand